Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.
Comparative Evaluation of Safety and Effectiveness of Autologous Bone Marrow Derived Mesenchymal Stem Cells (BM-MSC) vs Adipose Tissue Derived Mesenchymal Stem Cells (AT-MSC) in the Treatment of Spinal Cord Injury (SCI) Patient.
Sponsor: University of Jordan
Listed as NCT02981576, this PHASE1/PHASE2 trial focuses on Spinal Cord Injuries and remains completed. Sponsored by University of Jordan, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Feb 2019 — Oct 2019 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Jordan
For direct contact, visit the study record on ClinicalTrials.gov .